An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
Feature|Articles|July 20, 2026
Half a Year Into the Breast Biopsy Needle Shortage, Clinicians Lean on Networks, Not Workarounds
Author(s)Ariana Pelosci
Fact checked by: Tim Cortese
A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.
Advertisement
Advertisement
When Hologic recalled its Brevera Breast Biopsy System disposable 9-gauge needle on January 2, 2026, citing a risk of metal and plastic particles dislodging into patients or specimens during use, the ripple effects were felt across breast oncology.1 The needle wasn’t a niche product. It was one of the main products used by radiologists for breast biopsy imaging.
Related to this article
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.
Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient selection is the unifying theme.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
Advertisement
Advertisement